1. Home
  2. FNLC vs DCTH Comparison

FNLC vs DCTH Comparison

Compare FNLC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

N/A

Current Price

$28.24

Market Cap

306.9M

Sector

Finance

ML Signal

N/A

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.06

Market Cap

363.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
DCTH
Founded
1864
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
363.5M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
FNLC
DCTH
Price
$28.24
$11.06
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
8.6K
395.9K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
5.19%
N/A
EPS Growth
26.34
107.53
EPS
0.80
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
$34.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.36
$8.12
52 Week High
$30.33
$18.23

Technical Indicators

Market Signals
Indicator
FNLC
DCTH
Relative Strength Index (RSI) 46.22 53.17
Support Level $25.98 $10.17
Resistance Level $28.55 $11.24
Average True Range (ATR) 0.65 0.57
MACD -0.12 -0.05
Stochastic Oscillator 24.35 46.62

Price Performance

Historical Comparison
FNLC
DCTH

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: